BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 16/03/2011

Regulatory Body Hosts Public Workshop to Discuss Strategies for Minimizing Blood Clot Risk in IVIG Products

The FDA is hosting a public workshop to discuss potential procoagulant activity in Immune Globulin Intravenous (IVIG) products and strategies to mitigate this risk, following recent reports of adverse events associated with these treatments.

Source: Federal Register — Health and Human ServicesOpen original release →